Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Remme

Showing results (171-180 of 236) with videos related to

Pageof 24
Sort By:
Circulation. Heart Failure|March 23, 2012
When to stop a clinical trial early for benefit: lessons learned and future approachesFaiez Zannad, Wendy Gattis Stough, John J V McMurray, et al.
Cardiovascular Research|December 5, 2006
ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENTClaudio Ceconi, Kim M Fox, William J Remme, et al.
Tropical Medicine and Parasitology : Official Organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft Fur Technische Zusammenarbeit (GTZ)|September 1, 1989
A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. I. Effect on the microfilarial reservoir and the transmission of Onchocerca volvulusJ Remme, R H Baker, G De Sole, et al.
Journal of Cardiovascular Pharmacology|November 1, 1994
Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failureW J Remme, D A Kruijssen, D C van Hoogenhuyze, et al.
Heart (British Cardiac Society)|December 1, 2006
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA studyAndrew Briggs, Borislava Mihaylova, Mark Sculpher, et al.
European Heart Journal|May 18, 1999
Sustained benefit at 10-14 years follow-up after thrombolytic therapy in myocardial infarctionA C Maas, R T van Domburg, J W Deckers, et al.
European Heart Journal|April 7, 2009
The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trialsJasper J Brugts, Toshiharu Ninomiya, Eric Boersma, et al.
The British Journal of Dermatology|July 1, 1995
Bullous pemphigoid successfully controlled by tetracycline and nicotinamideD N Kolbach, J J Remme, W H Bos, et al.
European Heart Journal|April 1, 1990
Neurohumoral activation during acute myocardial ischaemia. Effects of ACE inhibitionW J Remme, M P Look, M Bootsma, et al.
Bulletin of the World Health Organization|January 1, 1989
Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trialsG De Sole, J Remme, K Awadzi, et al.
Pageof 24

Showing results (171-180 of 236) with videos related to

Sort By:
Pageof 24
Circulation. Heart Failure|March 23, 2012
When to stop a clinical trial early for benefit: lessons learned and future approachesFaiez Zannad, Wendy Gattis Stough, John J V McMurray, et al.
Cardiovascular Research|December 5, 2006
ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENTClaudio Ceconi, Kim M Fox, William J Remme, et al.
Tropical Medicine and Parasitology : Official Organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft Fur Technische Zusammenarbeit (GTZ)|September 1, 1989
A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. I. Effect on the microfilarial reservoir and the transmission of Onchocerca volvulusJ Remme, R H Baker, G De Sole, et al.
Journal of Cardiovascular Pharmacology|November 1, 1994
Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failureW J Remme, D A Kruijssen, D C van Hoogenhuyze, et al.
Heart (British Cardiac Society)|December 1, 2006
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA studyAndrew Briggs, Borislava Mihaylova, Mark Sculpher, et al.
European Heart Journal|May 18, 1999
Sustained benefit at 10-14 years follow-up after thrombolytic therapy in myocardial infarctionA C Maas, R T van Domburg, J W Deckers, et al.
European Heart Journal|April 7, 2009
The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trialsJasper J Brugts, Toshiharu Ninomiya, Eric Boersma, et al.
The British Journal of Dermatology|July 1, 1995
Bullous pemphigoid successfully controlled by tetracycline and nicotinamideD N Kolbach, J J Remme, W H Bos, et al.
European Heart Journal|April 1, 1990
Neurohumoral activation during acute myocardial ischaemia. Effects of ACE inhibitionW J Remme, M P Look, M Bootsma, et al.
Bulletin of the World Health Organization|January 1, 1989
Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trialsG De Sole, J Remme, K Awadzi, et al.
Pageof 24